This difference is likely due to the primary involvement of PD-1 in the regulation of peripheral effector responses within inflamed tissues and the tumor microenvironment, as opposed to CTLA-4, which primarily regulates the priming phase of the T cell response within the lymph nodes. The gene discussed is PDCD1; the disease is neoplasm.